WRBY Quote, Financials, Valuation and Earnings

Daxor Corp. has a net margin of 2.65% compared to Warby Parker, Inc.'s net margin of --. Warby Parker, Inc.'s return on equity of 0.2% beat Daxor Corp.'s return on equity of 1.57%.

Warby Parker, Inc. has a consensus price target of $22.45, signalling upside risk potential of 20.34%. On the other hand Daxor Corp. has an analysts' consensus of $22.00 which suggests that it could grow by 71.21%. Given that Daxor Corp. has higher upside potential than Warby Parker, Inc., analysts believe Daxor Corp. is more attractive than Warby Parker, Inc..

Warby Parker, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Daxor Corp. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100.015%.

Warby Parker, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Daxor Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Warby Parker, Inc. pays -- of its earnings as a dividend. Daxor Corp. pays out -- of its earnings as a dividend.

Warby Parker, Inc. quarterly revenues are $221.7M, which are larger than Daxor Corp. quarterly revenues of --. Warby Parker, Inc.'s net income of $5.9M is higher than Daxor Corp.'s net income of --. Notably, Warby Parker, Inc.'s price-to-earnings ratio is 4,847.37x while Daxor Corp.'s PE ratio is 35.23x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Warby Parker, Inc. is 2.67x versus 59.58x for Daxor Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Phibro Animal Health Corp. has a net margin of 2.65% compared to Warby Parker, Inc.'s net margin of 7.29%. Warby Parker, Inc.'s return on equity of 0.2% beat Phibro Animal Health Corp.'s return on equity of 24.77%.

Warby Parker, Inc. has a consensus price target of $22.45, signalling upside risk potential of 20.34%. On the other hand Phibro Animal Health Corp. has an analysts' consensus of $43.00 which suggests that it could grow by 5.47%. Given that Warby Parker, Inc. has higher upside potential than Phibro Animal Health Corp., analysts believe Warby Parker, Inc. is more attractive than Phibro Animal Health Corp..

Warby Parker, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Phibro Animal Health Corp. has a beta of 0.771, suggesting its less volatile than the S&P 500 by 22.868%.

Warby Parker, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Phibro Animal Health Corp. offers a yield of 1.18% to investors and pays a quarterly dividend of $0.12 per share. Warby Parker, Inc. pays -- of its earnings as a dividend. Phibro Animal Health Corp. pays out 40.46% of its earnings as a dividend. Phibro Animal Health Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Warby Parker, Inc. quarterly revenues are $221.7M, which are smaller than Phibro Animal Health Corp. quarterly revenues of $363.9M. Warby Parker, Inc.'s net income of $5.9M is lower than Phibro Animal Health Corp.'s net income of $26.5M. Notably, Warby Parker, Inc.'s price-to-earnings ratio is 4,847.37x while Phibro Animal Health Corp.'s PE ratio is 24.51x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Warby Parker, Inc. is 2.67x versus 1.19x for Phibro Animal Health Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Precision Optics Corp., Inc. has a net margin of 2.65% compared to Warby Parker, Inc.'s net margin of -24.5%. Warby Parker, Inc.'s return on equity of 0.2% beat Precision Optics Corp., Inc.'s return on equity of -54.55%.

Warby Parker, Inc. has a consensus price target of $22.45, signalling upside risk potential of 20.34%. On the other hand Precision Optics Corp., Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Warby Parker, Inc. has higher upside potential than Precision Optics Corp., Inc., analysts believe Warby Parker, Inc. is more attractive than Precision Optics Corp., Inc..

Warby Parker, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Precision Optics Corp., Inc. has a beta of 0.296, suggesting its less volatile than the S&P 500 by 70.404%.

Warby Parker, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Precision Optics Corp., Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Warby Parker, Inc. pays -- of its earnings as a dividend. Precision Optics Corp., Inc. pays out -- of its earnings as a dividend.

Warby Parker, Inc. quarterly revenues are $221.7M, which are larger than Precision Optics Corp., Inc. quarterly revenues of $6.7M. Warby Parker, Inc.'s net income of $5.9M is higher than Precision Optics Corp., Inc.'s net income of -$1.6M. Notably, Warby Parker, Inc.'s price-to-earnings ratio is 4,847.37x while Precision Optics Corp., Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Warby Parker, Inc. is 2.67x versus 1.40x for Precision Optics Corp., Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Sanara MedTech, Inc. has a net margin of 2.65% compared to Warby Parker, Inc.'s net margin of 3.17%. Warby Parker, Inc.'s return on equity of 0.2% beat Sanara MedTech, Inc.'s return on equity of -20.48%.

Warby Parker, Inc. has a consensus price target of $22.45, signalling upside risk potential of 20.34%. On the other hand Sanara MedTech, Inc. has an analysts' consensus of $41.00 which suggests that it could grow by 88.07%. Given that Sanara MedTech, Inc. has higher upside potential than Warby Parker, Inc., analysts believe Sanara MedTech, Inc. is more attractive than Warby Parker, Inc..

Warby Parker, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Sanara MedTech, Inc. has a beta of 1.182, suggesting its more volatile than the S&P 500 by 18.199%.

Warby Parker, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sanara MedTech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Warby Parker, Inc. pays -- of its earnings as a dividend. Sanara MedTech, Inc. pays out -- of its earnings as a dividend.

Warby Parker, Inc. quarterly revenues are $221.7M, which are larger than Sanara MedTech, Inc. quarterly revenues of $26.3M. Warby Parker, Inc.'s net income of $5.9M is higher than Sanara MedTech, Inc.'s net income of $834.5K. Notably, Warby Parker, Inc.'s price-to-earnings ratio is 4,847.37x while Sanara MedTech, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Warby Parker, Inc. is 2.67x versus 1.84x for Sanara MedTech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.